NKTR
Nektar Therapeutics
NASDAQ · Pharmaceuticals
$36.81
+1.69 (+4.81%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 146.03M | 147.73M | 233.30M | 246.52M | 245.87M |
| Net Income | -176,493,789 | -160,692,372 | 47.46M | 56.66M | 62.08M |
| EPS | — | — | — | — | — |
| Profit Margin | -120.9% | -114.8% | 20.3% | 23.0% | 25.3% |
| Rev Growth | -1.2% | -1.2% | +12.6% | +15.2% | +17.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 306.15M | 257.51M | 280.38M |
| Total Equity | — | — | 308.72M | 292.45M | 319.03M |
| D/E Ratio | — | — | 0.99 | 0.88 | 0.88 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -150,139,228 | -144,291,620 | 100.43M | 106.98M | 112.84M |
| Free Cash Flow | — | — | 58.83M | 45.61M | 47.98M |